HER2 copy-number amplification was demonstrated in 2–22% of NSCLC, and HER2 overexpression was seen in 7.7–23%, with variations depending on the analytical methods used and populations examined [56]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.